Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Meningococcal Vaccines Market Size From 2025 to 2034?

The market size of meningococcal vaccines has experienced substantial growth in the recent past. Projections indicate it will expand from $3.89 billion in 2024 to $4.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. Factors such as disease occurrence, global travel patterns, healthcare framework, epidemic readiness, and health insurance coverage have contributed to the historic period’s growth.

In the coming years, the meningococcal vaccines market is projected to experience significant expansion. The market is set to reach a value of $6.05 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period is due to various factors such as the emergence of new strains, expanding globalization, increased healthcare investments, health initiatives and modifications in regulatory frameworks. Notable trends expected over the forecast period include personalized vaccines, digitization of vaccination records, advancements in gene-editing technologies, multivalent vaccines, and the expansion of subscription-based vaccination models.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Meningococcal Vaccines Market?

The expected surge in healthcare expenditures is set to fuel the expansion of the meningococcal vaccine market. Healthcare encompasses residential care establishments, nursing facilities, intermediate care homes for individuals with mental health issues, or intermediate support institutions for those with intellectual disabilities. The higher costs associated with new generations of vaccines, in comparison to their forerunners, have taken center stage in debates concerning whether the benefits of these new vaccinations outweigh their costly prices. The thorough appraisal of the social and economic benefits of vaccinations is emerging as a vital field of study in the literature on vaccination value. For instance, in May 2022, as per a report released by the American Medical Association, a professional body and advocating group for US physicians and medical trainees, the United States saw a 9.7% surge in healthcare spending to $4.1 trillion or $12,530 per individual. This rate of growth markedly outpaces that of 2019 (4.3%) Hence, the boom in healthcare spending is crucial to the growth of the meningococcal vaccine market.

Which Key Market Segments Comprise the Meningococcal Vaccines Market and Drive Its Revenue Growth?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Which Areas Are Leading Regions in the Meningococcal Vaccines Market Expansion Across the Globe?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theMeningococcal Vaccines Market Over the Coming Years?

New vaccines to prevent certain serogroups are being developed by key players in the meningococcal vaccines market as a strategic move to enhance their market profitability. Meningococcal vaccines are preventive solutions that help protect individuals from infections caused by various serogroups of Neisseria meningitidis bacteria. For instance, Pfizer Inc., a prominent pharmaceutical firm based in the USA, received FDA approval for their vaccine PENBRAYA in October 2023. PENBRAYA holds the distinction of having the most extensive serogroup coverage among U.S.-approved meningococcal vaccines, providing protection against groups A, B, C, W, and Y. This FDA approval is backed by strong evidence from Phase 2 and 3 clinical trials, which confirmed its immunogenicity to be comparable with Trumenba + Menveo across all serogroups and also demonstrated favorable safety. In September 2022, Pfizer also announced positive results from a Phase 3 trial, wherein PENBRAYA was compared with licensed meningococcal vaccines currently in use with regard to safety, tolerability, and immunogenicity.

View the full report here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

How Is the Meningococcal Vaccines Market Conceptually Defined?

Meningococcal vaccinations are vaccines that protect against meningococcal meningitis, an infection with the bacterium Neisseria meningitides that leads to inflammation of the tissues that surround the brain and spinal cord.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model